• Explore /
  • Poster
  • / A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity.

A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity.

Abstract Poster

Authors

Joan Carles

Joan Carles

Hosp Universitari de Vall d'Hebron

Joan Carles , Enrique Gallardo Diaz , Montserrat Domenech , Albert Font , Joaquim Bellmunt , Begoña Mellado , Cristina Suárez , Teresa Bonfill , M Isabel Saez , Marta Guix , Maria Jose Mendez , Pablo Maroto , Teresa de Portugal , Mariona Figols , Raquel Luque , Ramon Aldabo , Rafael Morales , Marta Bonet , Xavier Maldonado , Palmira Foro

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Localized Disease

Clinical Trial Registration Number

2008-003554-14

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 15)

DOI

10.1200/jco.2015.33.7_suppl.15

Abstract #

15

Poster Bd #

B7

Abstract Disclosures

Similar Posters

Poster

2020 Genitourinary Cancers Symposium

Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.

Adjuvant docetaxel for high-risk localized prostate cancer: Update of NRG Oncology/RTOG 0521.

First Author: Howard M. Sandler

First Author: Isabel Syndikus

First Author: Sagar A. Patel

First Author: Jonathan W. Lischalk